🧪 Hypotheses

therapeutic 0.89

APOE-Dependent Autophagy Restoration

🧬 MTOR 🏥 neurodegeneration 📖 56🏛 3

✅ 0.90 ✨ 0.60 💥 0.80

## Mechanistic Overview...

therapeutic 0.88

Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation

🧬 HCRTR1/HCRTR2 🏥 neurodegeneration 📖 37🏛 2

✅ 0.90 ✨ 0.75 💥 0.80

## Mechanistic Overview...

therapeutic 0.85

Senescent Cell ASM-Complement Cascade Intervention

🧬 SMPD1 🏥 neurodegeneration 📖 54🏛 1

✅ 0.68 ✨ 0.78 💥 0.75

## Mechanistic Overview...

therapeutic 0.84

Neutral Sphingomyelinase-2 Inhibition for Synaptic Protection in Neurodegeneration

🧬 SMPD3 🏥 neurodegeneration 📖 45🏛 1

✅ 0.68 ✨ 0.78 💥 0.75

## Mechanistic Overview...

therapeutic 0.83

AMPK hypersensitivity in astrocytes creates enhanced mitochondrial rescue responses

🧬 PRKAA1 🏥 neurodegeneration 📖 45🏛 2

✅ 0.85 ✨ 0.80 💥 0.75

## Mechanistic Overview...

therapeutic 0.82

CYP46A1 Small Molecule Activator Therapy

🧬 CYP46A1 🏥 neurodegeneration 📖 47🏛 3

✅ 0.75 ✨ 0.71 💥 0.76

This approach employs pharmacological activation of endogenous CYP46A1 rather than gene overexpression to treat Alzheimer's disease through enhanced b...

therapeutic 0.82

CYP46A1-Mediated Cholesterol Reduction Prevents eIF2α-Driven Translation Stalling in Neurodegeneration

🧬 CYP46A1 🏥 neurodegeneration 📖 47🏛 3

✅ 0.75 ✨ 0.71 💥 0.76

This hypothesis proposes that CYP46A1 overexpression gene therapy prevents neurodegeneration by disrupting the pathological link between cholesterol d...

therapeutic 0.81

Extracellular Vesicle Biogenesis Modulation

🧬 CHMP4B 🏥 neurodegeneration 📖 29🏛 1

✅ 0.35 ✨ 0.63 💥 0.00

## Mechanistic Overview...

therapeutic 0.81

LRP1-Dependent Tau Uptake Disruption

🧬 LRP1 🏥 neurodegeneration 📖 23🏛 1

✅ 0.29 ✨ 0.35 💥 0.00

## Mechanistic Overview...

therapeutic 0.81

Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuroinflammation

🧬 HCAR2 🏥 neurodegeneration 📖 11🏛 1

✅ 0.82 ✨ 0.70 💥 0.75

## Mechanistic Overview...

therapeutic 0.80

Targeted Butyrate Supplementation for Microglial Phenotype Modulation

🧬 GPR109A 🏥 neurodegeneration 📖 29🏛 3

✅ 0.90 ✨ 0.60 💥 0.80

## Mechanistic Overview...

therapeutic 0.80

Microglial TREM2-SYK Pathway Enhancement

🧬 TREM2 🏥 neurodegeneration 📖 8🏛 2

✅ 0.70 ✨ 0.60 💥 0.80

## Mechanistic Overview...

therapeutic 0.79

Senescent Microglia Resolution via Maresins-Senolytics Combination

🧬 BCL2L1 🏥 neurodegeneration 📖 25🏛 2

✅ 0.70 ✨ 0.80 💥 0.80

## Mechanistic Overview...

therapeutic 0.79

Selective TLR4 Modulation to Prevent Gut-Derived Neuroinflammatory Priming

🧬 TLR4 🏥 neurodegeneration 📖 45🏛 3

✅ 0.80 ✨ 0.70 💥 0.70

## Mechanistic Overview...

therapeutic 0.79

VCP-Mediated Autophagy Enhancement

🧬 VCP 🏥 neurodegeneration 📖 38🏛 1

✅ 0.64 ✨ 0.37 💥 0.00

## Mechanistic Overview...

therapeutic 0.78

Selective Acid Sphingomyelinase Modulation Therapy

🧬 SMPD1 🏥 neurodegeneration 📖 39🏛 2

✅ 0.79 ✨ 0.65 💥 0.74

## Mechanistic Overview...

therapeutic 0.78

Selective HDAC3 Inhibition with Cognitive Enhancement

🧬 HDAC3 🏥 neurodegeneration 📖 48🏛 3

✅ 0.70 ✨ 0.85 💥 0.80

## Mechanistic Overview...

therapeutic 0.77

Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation

🧬 FCGRT 🏥 neurodegeneration 📖 44🏛 2

✅ 0.70 ✨ 0.60 💥 0.60

## Mechanistic Overview...

therapeutic 0.77

Chromatin Accessibility Restoration via BRD4 Modulation

🧬 BRD4 🏥 neurodegeneration 📖 49🏛 3

✅ 0.60 ✨ 0.90 💥 0.70

## Mechanistic Overview...

therapeutic 0.77

CYP46A1 Overexpression Gene Therapy

🧬 CYP46A1 🏥 neurodegeneration 📖 47🏛 3

✅ 0.73 ✨ 0.71 💥 0.77

## Mechanistic Overview...

therapeutic 0.77

HDL/apoE Particle Remodeling as a Therapeutic Switch for CAA Prevention

🧬 ABCA1 🏥 neurodegeneration 📖 20🏛 1

✅ 0.61 ✨ 0.55 💥 0.72

## Mechanistic Overview...

therapeutic 0.76

Repeat-domain exposure defines seed-competent tau conformers

🧬 MAPT 🏥 neurodegeneration 📖 8🏛 1

✅ 0.70 ✨ 0.62 💥 0.88

Tau assemblies become seed-competent when their repeat-domain surfaces adopt a conformation that both survives transfer and templates monomeric tau in...

therapeutic 0.76

Targeted APOE4-to-APOE3 Base Editing Therapy

🧬 APOE 🏥 neurodegeneration 📖 62🏛 2

✅ 0.20 ✨ 0.90 💥 0.90

**Molecular Mechanism and Rationale**...

therapeutic 0.76

Night-phase orexin receptor antagonism rescues AD by restoring sleep-dependent clearance

🧬 HCRTR2 🏥 neurodegeneration 📖 8🏛 1

✅ 0.84 ✨ 0.58 💥 0.76

Timed OX1R/OX2R antagonism during the rest phase may consolidate sleep, improve glymphatic/interstitial clearance, and reduce amyloid or tau stress wh...

therapeutic 0.76

Senescence-Activated NAD+ Depletion Rescue

🧬 CD38/NAMPT 🏥 neurodegeneration 📖 35🏛 2

✅ 0.70 ✨ 0.75 💥 0.75

## Mechanistic Overview...

therapeutic 0.75

Dopaminergic Ventral Tegmental-Hippocampal Circuit Protection

🧬 MAPT 🏥 neuroscience 📖 17🏛 3

✅ 0.70 ✨ 0.75 💥 0.72

## Mechanistic Overview...

therapeutic 0.75

C1QA/C1QB Subunit-Specific Inhibition to Block Aberrant PV Interneuron Input Elimination in Alzheimer's Disease

🧬 C1QA, C1QB 🏥 neurodegeneration 📖 11🏛 1

✅ 0.45 ✨ 0.58 💥 0.65

**Molecular Mechanism and Rationale**...

therapeutic 0.74

GPX4 reserve failure gates selective ALS motor-neuron ferroptosis

🧬 GPX4 🏥 neurodegeneration 📖 8🏛 1

✅ 0.72 ✨ 0.61 💥 0.86

ALS-linked proteostasis stress lowers effective GPX4 reserve in vulnerable motor neurons, allowing oxidized phospholipids to cross a ferroptotic death...

therapeutic 0.74

Circadian-Synchronized Proteostasis Enhancement

🧬 CLOCK/ULK1 🏥 neurodegeneration 📖 28🏛 2

✅ 0.60 ✨ 0.80 💥 0.70

# Detailed Scientific Description: Circadian-Synchronized Proteostasis Enhancement...

therapeutic 0.74

Near-infrared light therapy stimulates COX4-dependent mitochondrial motility enhancement

🧬 COX4I1 🏥 neurodegeneration 📖 50🏛 2

✅ 0.90 ✨ 0.75 💥 0.65

## Mechanistic Overview...